Last updated: February 22, 2026
What Is NDC 69238-2090?
NDC 69238-2090 is a drug marketed as Emgality (galcanezumab-gnlm), a monoclonal antibody used primarily for the prevention of migraine and cluster headaches. Approved by the FDA in September 2018, it is manufactured by Eli Lilly. The drug is administered via subcutaneous injection and represented a significant entry into the CGRP inhibitor class.
Market Overview
Current Market Size
As of 2023, the global migraine treatment market was valued at approximately $4 billion. The segment for CGRP inhibitors, including Emgality, accounts for about 30% of this total.
| Segment |
Market Share |
Estimated Value (USD billions) |
| Traditional migraine therapies |
70% |
2.8 |
| CGRP inhibitors (including Emgality) |
30% |
1.2 |
Competitive Landscape
Emgality's main competitors include:
- Aimovig (erenumab) by Novartis
- Ajovy (fremanezumab) by Teva
- Vyepti (eptinezumab) by Lundbeck/AbbVie
These drugs have similar indications and routes of administration but vary in dosing frequency, efficacy profiles, and pricing.
Market Penetration
Emgality has gained rapid adoption owing to its efficacy in reducing migraine days. As of 2023, approximately 35% of CGRP inhibitor prescriptions are for Emgality, highlighting its strong market position but leaving room for growth.
Pricing Analysis
Current Pricing
- Average Wholesale Price (AWP): Approximately USD 800 per injection.
- Average Selling Price (ASP): Estimated USD 650–700 per injection.
- Dosing Schedule: Typically, monthly for the first three months, then quarterly, leading to annual costs of around USD 8,000–10,000 per patient.
Pricing Trends
Since launch, prices have remained relatively stable, with minimal discounts for insurance or pharmacy benefit managers.
Cost-Effectiveness
Studies indicate that Emgality's cost per Quality-Adjusted Life Year (QALY) gained varies from USD 50,000 to USD 100,000, placing it within acceptable ranges for chronic disease treatments in high-income markets.
Market Forecasts
Demand Growth Projections
- CAGR (2023–2028): 8–10%
- Drivers: Increasing awareness, expanding indications (e.g., chronic migraine, cluster headache), and improved insurance coverage.
Revenue Projections
| Year |
Estimated Revenue (USD millions) |
| 2023 |
480 |
| 2024 |
520 |
| 2025 |
560 |
| 2026 |
610 |
| 2027 |
660 |
By 2027, global revenues could approach USD 700 million, contingent on market penetration rates and pricing strategies.
Price Projection Factors
- Patent Status: Expiry anticipated around 2028–2029, which could influence pricing through biosimilar entry.
- Market Competition: Introduction of biosimilars may prompt price reductions of 20–40%.
- Healthcare Policies: Payor negotiations and value-based pricing models could exert downward pressure on prices.
Impact of Biosimilar Competition
Entry of biosimilars typically reduces prices by 25–40%. For Emgality, bioequivalent alternatives could enter the market around 2028. This will likely result in significant price erosion and market share redistribution.
Risks and Opportunities
Risks
- Patent expiration leading to biosimilar competition.
- Regulatory hurdles in new markets.
- Pricing pressure from payors.
Opportunities
- Expansion into new indications.
- Geographic expansion into emerging markets.
- Development of combination therapies.
Summary
Emgality (NDC 69238-2090) is a leading CGRP inhibitor with stable pricing and a solid market share. Price projections suggest modest growth with potential reductions post-patent expiry due to biosimilar competition. The market remains dynamic, driven by increased adoption, pipeline expansion, and regulatory developments.
Key Takeaways
- Emgality's annual cost remains around USD 8,000–10,000 per patient.
- The global migraine market is projected to grow at 8–10% CAGR through 2028.
- Biosimilar competition is expected to lead to pricing reductions starting around 2028.
- Market share is most likely to stabilize near 35% among CGRP inhibitors but could shift with new entrants.
- Strategic expansion into emerging markets and indications presents growth opportunities.
FAQs
1. When is biosimilar competition likely to impact Emgality prices?
Biosimilar versions are expected to enter the market around 2028–2029, potentially reducing prices by 25–40%.
2. How does Emgality compare in price to its competitors?
Prices are comparable, with injection costs averaging USD 800 per dose; however, dosing frequency influences total annual costs.
3. What is the primary driver of growth in Emgality's sales?
Increasing adoption for migraines and cluster headaches, coupled with pipeline expansions and geographic growth.
4. Are there any regulatory barriers for Emgality in emerging markets?
Yes, regulatory approval processes vary across countries, potentially delaying market entry and affecting pricing strategies.
5. What potential does Emgality have beyond migraine prevention?
Studies are ongoing for additional indications such as menstrual migraines and other pain syndromes; success could diversify revenue streams.
References
[1] Allied Market Research. (2023). CGRP Inhibitors Market Report.
[2] FDA. (2018). Press Release on Emgality Approval.
[3] IQVIA. (2023). Global Prescription Data.
[4] WHO. (2021). Cost-Effectiveness Analysis in Chronic Disease.
[5] Eli Lilly. (2023). Emgality Prescribing Information.
